• Profile
Close

Galectin-3 and S100A9: Novel diabetogenic factors mediating pancreatic cancer-associated diabetes

Diabetes Care Jul 05, 2019

Liao WC, et al. - In this investigation, researchers identified pancreatic cancer-associated diabetes (PCDM) mediators and assessed their utility in differentiating PCDM from type 2 diabetes. Secreted proteins of MIA PaCa-2 cells were recognized by proteomics, and those with ≥10-fold overexpression in transcriptome analysis were evaluated by bioinformatics and glucose uptake assay to identify candidate factors. In PCDM tumors, galectin-3 and S100A9 are overexpressed and mediate insulin resistance. In subjects with new-onset diabetes, galectin-3 and S100A9 distinguish PCDM from type 2 diabetes.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay